Researchers identified genetic predictors of relapse in standard risk B-cell acute lymphoblastic leukemia highlighting the role of...

In a report published in Nature Medicine, St. Jude scientists examined how ALL cells respond to different therapeutics in the context of...

Kinase inhibitor trametinib may spare patients from intensive treatments, such as stem cell transplant, for an aggressive form of blood...

Investigators from St. Jude Children’s Research Hospital and collaborators worldwide have uncovered distinguishing characteristics for a...

The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile...

A team of researchers has demonstrated that some childhood leukemias originate during embryonic development, although they do not...

Children conceived via fresh or frozen embryo transfer may have increased risk for acute lymphoblastic leukemia compared with children...

Scientists at St. Jude Children’s Research Hospital have discovered non-coding genetic variants contributing to chemotherapy resistance...

Researchers have developed a functional precision medicine approach that targets cancer by combining genetic testing with a new way to...

By characterizing B-cells’ developmental stages, scientists at St. Jude Children’s Research Hospital designed and tested a drug...